Results 181 to 190 of about 224,938 (296)

Mace Oil [PDF]

, 2020
openaire   +1 more source

Semaglutide 2.4 mg Cardiometabolic Long‐Term Effects in Patients With Obesity or Overweight in a Real‐World Setting: A Retrospective Cohort Study in the United States (SMILE)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the real‐world associations between semaglutide 2.4 mg and cardiometabolic comorbidities, biomarkers and cardiovascular risk among adults with overweight or obesity. Methods This retrospective cohort study used US claims data and laboratory measurements from the Komodo Research Database (2016–2024). Adults with obesity or with
Aleksandrina Ruseva, Wojciech Michalak, Matthew Bassan, Ella Xiaoyan Du, Anthony Fabricatore, Bríain Ó Hartaigh, Theo Man, Ramya Ramasubramanian, Pangsibo Shen, Jinlin Song, Zhenxiang Zhao, Francisco Lopez‐Jimenez   +11 more
wiley   +1 more source

Machine learning potential for modelling dynamic hydrogen bond networks in MOF MIL-120. [PDF]

Chem Sci
Jin X, Li Y, Gaedecke K, Zhang X, Smit B.   +4 more
europepmc   +1 more source

Prognostic value of mitral annular plane systolic excursion for adverse cardiovascular events in patients with acute myocarditis. [PDF]

Front Cardiovasc Med
Ren R, Zhao Q, Li W, Zhang Y, Xu X, Lv L, Zhang Y.   +6 more
europepmc   +1 more source

Regional Ocean Governance: A Look at California [PDF]

, 2006
Baird, Brian E., Mace, Amber J.
core   +1 more source

Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim We compared the impact of metabolic bariatric surgery (MBS) versus semaglutide on clinical outcomes in individuals with metabolic dysfunction‐associated steatotic liver disease (MASLD) and type 2 diabetes (T2D). Methods Patients with MASLD and T2D who had MBS or semaglutide in 2018–2023 were identified (TriNetX database).
Weronika Stupalkowska, Alex E. Henney, David R. Riley, Eric G. Sheu, Uazman Alam, Daniel J. Cuthbertson   +5 more
wiley   +1 more source

Specific gut microbes are associated with the incidence of cardiometabolic disease in the HELIUS cohort. [PDF]

NPJ Biofilms Microbiomes
Verhaar BJH, Bouwmeester TA, Galenkamp H, van den Born BH, Nieuwdorp M.   +4 more
europepmc   +1 more source

Statistical energy analysis and finite elements

, 2003
Mace, B.R.
core  

Serum IGF‐1 and the Risk of Cardio‐Kidney Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) increases cardiovascular and kidney disease risk. Insulin‐like growth factor 1 (IGF‐1) regulates metabolic and vascular function, but its role in long‐term cardio‐kidney outcomes (CKO) in MASLD remains unclear.
Yongin Cho, Hye‐Sun Park, Tae Seop Lim, Jong Ho Jhee, Jong Hyun Jhee   +4 more
wiley   +1 more source

Relationship of intraoperative hypotension with major adverse cardiovascular events and acute kidney injury after pancreaticoduodenectomy. [PDF]

Front Med (Lausanne)
Yu F, Wei Y, Huang J, Chu X, Wu L, Chen R, Wang X, Hu Y.   +7 more
europepmc   +1 more source